Clinical Trial Update: A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA

View source ↗

Summary

This trial update notes that the phase I imaging study of the radiopharmaceutical 18F-FAZA for hypoxic tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoxic Tumors

Drugs mentioned

• 18F-FAZA (fluorine-18 labeled nitroimidazole PET radiotracer)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Hypoxic Tumours | Status: WITHDRAWN